{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T13:37:28Z","timestamp":1791466648713,"version":"4.3.4"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2019,5,30]],"date-time":"2019-05-30T00:00:00Z","timestamp":1559174400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2019,5,30]],"date-time":"2019-05-30T00:00:00Z","timestamp":1559174400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Pfizer Inc"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1007\/s12325-019-00986-7","type":"journal-article","created":{"date-parts":[[2019,5,30]],"date-time":"2019-05-30T12:02:40Z","timestamp":1559217760000},"page":"2086-2095","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Cost-Effectiveness of Early Treatment with Originator Biologics or Their Biosimilars After Methotrexate Failure in Patients with Established Rheumatoid Arthritis"],"prefix":"10.1007","volume":"36","author":[{"given":"Dipen","family":"Patel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Shelbaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jyoti","family":"Aggarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Hee","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Coindreau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,5,30]]},"reference":[{"key":"986_CR1","doi-asserted-by":"publisher","first-page":"18001","DOI":"10.1038\/nrdp.2018.1","volume":"4","author":"JS Smolen","year":"2018","unstructured":"Smolen JS, Aletaha D, Barton A, et al. Rheumatoid arthritis. Nat Rev Dis Primers. 2018;4:18001.","journal-title":"Nat Rev Dis Primers"},{"key":"986_CR2","unstructured":"World Health Organization. Chronic rheumatic conditions.\u00a02019. \n                    https:\/\/www.who.int\/chp\/topics\/rheumatic\/en\/\n                    \n                  . Accessed Feb 27, 2019."},{"key":"986_CR3","first-page":"rky005-rky05","volume":"2","author":"C-I Chen","year":"2018","unstructured":"Chen C-I, Wang L, Wei W, Yuce H, Phillips K. Burden of rheumatoid arthritis among US Medicare population: co-morbidities, health-care resource utilization and costs. Rheumatol Adv Pract. 2018;2:rky005-rky05.","journal-title":"Rheumatol Adv Pract"},{"key":"986_CR4","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1007\/s00296-015-3415-x","volume":"36","author":"PC Taylor","year":"2016","unstructured":"Taylor PC, Moore A, Vasilescu R, Alvir J, Tarallo M. A structured literature review of the burden of illness and unmet needs in patients with rheumatoid arthritis: a current perspective. Rheumatol Int. 2016;36:685\u201395.","journal-title":"Rheumatol Int"},{"issue":"Suppl 2","key":"986_CR5","doi-asserted-by":"publisher","first-page":"S49","DOI":"10.1007\/s10198-007-0088-8","volume":"8","author":"J Lundkvist","year":"2008","unstructured":"Lundkvist J, Kastang F, Kobelt G. The burden of rheumatoid arthritis and access to treatment: health burden and costs. Eur J Health Econ. 2008;8(Suppl 2):S49\u201360.","journal-title":"Eur J Health Econ"},{"key":"986_CR6","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1136\/annrheumdis-2013-203485","volume":"72","author":"P Emery","year":"2013","unstructured":"Emery P, Sebba A, Huizinga TW. Biologic and oral disease-modifying antirheumatic drug monotherapy in rheumatoid arthritis. Ann Rheum Dis. 2013;72:1897\u2013904.","journal-title":"Ann Rheum Dis"},{"key":"986_CR7","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1007\/s10067-014-2841-6","volume":"34","author":"M Al Maini","year":"2015","unstructured":"Al Maini M, Adelowo F, Al Saleh J, et al. The global challenges and opportunities in the practice of rheumatology: white paper by the World Forum on Rheumatic and Musculoskeletal Diseases. Clin Rheumatol. 2015;34:819\u201329.","journal-title":"Clin Rheumatol"},{"key":"986_CR8","unstructured":"European Medicines Agency. Guideline on similar biological medicinal products. CHMP\/437\/04 Rev. 1. 2014. \n                    http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2014\/10\/WC500176768.pdf\n                    \n                  . Accessed June 25, 2018."},{"key":"986_CR9","unstructured":"United States Food and Drug Administration. Considerations in demonstrating interchangeability with a reference product: guidance for industry. 2019. \n                    https:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM537135.pdf\n                    \n                  . Accessed May 16, 2019."},{"key":"986_CR10","unstructured":"World Health Organization, Expert Committee on Biological Standardization. Guidelines on evaluation of similar biotherapeutic products (SBPs). 2009. \n                    http:\/\/www.who.int\/biologicals\/areas\/biological_therapeutics\/BIOTHERAPEUTICS_FOR_WEB_22APRIL2010.pdf\n                    \n                  . Accessed June 25, 2018."},{"key":"986_CR11","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1136\/annrheumdis-2016-209166","volume":"75","author":"T Dorner","year":"2016","unstructured":"Dorner T, Strand V, Cornes P, et al. The changing landscape of biosimilars in rheumatology. Ann Rheum Dis. 2016;75:974\u201382.","journal-title":"Ann Rheum Dis"},{"key":"986_CR12","doi-asserted-by":"publisher","first-page":"235","DOI":"10.3899\/jrheum.121468","volume":"41","author":"EC Keystone","year":"2014","unstructured":"Keystone EC, Haraoui B, Guerette B, Mozaffarian N, Liu S, Kavanaugh A. Clinical, functional, and radiographic implications of time to treatment response in patients with early rheumatoid arthritis: a posthoc analysis of the PREMIER study. J Rheumatol. 2014;41:235\u201343.","journal-title":"J Rheumatol"},{"key":"986_CR13","doi-asserted-by":"publisher","first-page":"2784","DOI":"10.1002\/art.22052","volume":"54","author":"D Aletaha","year":"2006","unstructured":"Aletaha D, Smolen J, Ward MM. Measuring function in rheumatoid arthritis: identifying reversible and irreversible components. Arthritis Rheum. 2006;54:2784\u201392.","journal-title":"Arthritis Rheum"},{"key":"986_CR14","first-page":"316","volume":"34","author":"H Makinen","year":"2007","unstructured":"Makinen H, Kautiainen H, Hannonen P, et al. Sustained remission and reduced radiographic progression with combination disease modifying antirheumatic drugs in early rheumatoid arthritis. J Rheumatol. 2007;34:316\u201321.","journal-title":"J Rheumatol"},{"key":"986_CR15","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1002\/art.24447","volume":"60","author":"V Rantalaiho","year":"2009","unstructured":"Rantalaiho V, Korpela M, Hannonen P, et al. The good initial response to therapy with a combination of traditional disease-modifying antirheumatic drugs is sustained over time: the eleven-year results of the Finnish rheumatoid arthritis combination therapy trial. Arthritis Rheum. 2009;60:1222\u201331.","journal-title":"Arthritis Rheum"},{"key":"986_CR16","doi-asserted-by":"publisher","first-page":"e000057","DOI":"10.1136\/rmdopen-2015-000057","volume":"1","author":"S Monti","year":"2015","unstructured":"Monti S, Montecucco C, Bugatti S, Caporali R. Rheumatoid arthritis treatment: the earlier the better to prevent joint damage. RMD Open. 2015;1:e000057.","journal-title":"RMD Open"},{"key":"986_CR17","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1002\/acr.20338","volume":"63","author":"G van der Velde","year":"2011","unstructured":"van der Velde G, Pham B, Machado M, et al. Cost-effectiveness of biologic response modifiers compared to disease-modifying antirheumatic drugs for rheumatoid arthritis: a systematic review. Arthritis Care Res (Hoboken). 2011;63:65\u201378.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"986_CR18","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1056\/NEJMoa1608345","volume":"376","author":"PC Taylor","year":"2017","unstructured":"Taylor PC, Keystone EC, van der Heijde D, et al. Baricitinib versus placebo or adalimumab in rheumatoid arthritis. N Engl J Med. 2017;376:652\u201362.","journal-title":"N Engl J Med"},{"key":"986_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta15140","volume":"15","author":"K Malottki","year":"2011","unstructured":"Malottki K, Barton P, Tsourapas A, et al. Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation. Health Technol Assess. 2011;15:1\u2013278.","journal-title":"Health Technol Assess"},{"key":"986_CR20","doi-asserted-by":"publisher","first-page":"R77","DOI":"10.1186\/ar2997","volume":"12","author":"B Vander Cruyssen","year":"2010","unstructured":"Vander Cruyssen B, Durez P, Westhovens R, De Keyser F. Seven-year follow-up of infliximab therapy in rheumatoid arthritis patients with severe long-standing refractory disease: attrition rate and evolution of disease activity. Arthritis Res Ther. 2010;12:R77.","journal-title":"Arthritis Res Ther"},{"key":"986_CR21","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1136\/annrheumdis-2015-209058","volume":"76","author":"Y Zhang","year":"2017","unstructured":"Zhang Y, Lu N, Peloquin C, et al. Improved survival in rheumatoid arthritis: a general population-based cohort study. Ann Rheum Dis. 2017;76:408\u201313.","journal-title":"Ann Rheum Dis"},{"key":"986_CR22","doi-asserted-by":"publisher","first-page":"A532","DOI":"10.1016\/j.jval.2017.08.754","volume":"20","author":"J Capron","year":"2017","unstructured":"Capron J, De Leonardis F, Fakhouri W, Burke T, Rose A, Jacob I. The impact of disease duration and disease activity on the cost of rheumatoid arthritis: results from Burden of Rheumatoid Arthritis Across Europe a Socioeconomic Survey (BRASS). Value Health. 2017;20:A532.","journal-title":"Value Health"},{"key":"986_CR23","unstructured":"Department for Work & Pensions. Economic labour market status of individuals aged 50 and over, trends over time: September 2017 (experimental). Data for 1950 to 2017. 2017. \n                    https:\/\/assets.publishing.service.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/642157\/economic-labour-market-status-of-individuals-aged-50-and-over-since-1950.pdf\n                    \n                  . Accessed May 29, 2018."},{"key":"986_CR24","unstructured":"Muhammad R, Whyte L, Protheroe S, Bremner R, Haller W, Wong T. Comparison of efficacy and safety of biosimilar infliximab to originator infliximab in children with inflammatory bowel disease. 2016. \n                    https:\/\/www.ecco-ibd.eu\/publications\/congress-abstract-s\/item\/p382-comparison-of-efficacy-and-safety-of-biosimilar-infliximab-to-originator-infliximab-in-children-with-inflammatory-bowel-disease.html?highlight=WyJiaW9zaW1pbGFyIiwiYmlvc2ltaWxhcnMiLCJpbmZsaXhpbWFiIiwiYmlvc2ltaWxhciBpbmZsaXhpbWFiIl0\n                    \n                  . Accessed May 29, 2018."},{"key":"986_CR25","doi-asserted-by":"publisher","first-page":"2625","DOI":"10.1002\/art.21235","volume":"52","author":"D Aletaha","year":"2005","unstructured":"Aletaha D, Ward MM, Machold KP, Nell VP, Stamm T, Smolen JS. Remission and active disease in rheumatoid arthritis: defining criteria for disease activity states. Arthritis Rheum. 2005;52:2625\u201336.","journal-title":"Arthritis Rheum"},{"key":"986_CR26","doi-asserted-by":"publisher","first-page":"2310","DOI":"10.1002\/art.10471","volume":"46","author":"G Kobelt","year":"2002","unstructured":"Kobelt G, Jonsson L, Lindgren P, Young A, Eberhardt K. Modeling the progression of rheumatoid arthritis: a two-country model to estimate costs and consequences of rheumatoid arthritis. Arthritis Rheum. 2002;46:2310\u20139.","journal-title":"Arthritis Rheum"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-019-00986-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12325-019-00986-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-019-00986-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,28]],"date-time":"2020-05-28T23:21:35Z","timestamp":1590708095000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12325-019-00986-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,30]]},"references-count":26,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["986"],"URL":"https:\/\/doi.org\/10.1007\/s12325-019-00986-7","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,30]]},"assertion":[{"value":"9 April 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2019","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}